Merck to Acquire HUB Organoids Holding B.V., Advancing Organoid Technology in Drug Development
Merck (NYSE: MRK) has announced a definitive agreement with the intention to acquire HUB Organoids...
NYSE: MRK
Hansoh Pharmaceutical Secures Global Licensing Deal with Merck for HS-10535
China’s Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a significant global license deal...
MSD Halts Development of Vibostolimab and Favezelimab Due to Trial Setbacks
US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed its decision to...
European CHMP Supports Conditional Approval of MSD’s Welireg for VHL Disease and RCC
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the European Medicines Agency’s Committee...
AstraZeneca’s Lynparza Shows Sustained Improvements in OlympiA Phase III Study
UK pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has updated data from the Phase III OlympiA...
Merck’s PD-1 Inhibitor Keytruda Approved by NMPA for Cervical Cancer Treatment in China
US-based Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has announced receiving marketing approval from...
MSD’s Noxafil Receives NMPA Approval for Pediatric Use in Antifungal Treatment
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced that China’s National Medical...
Merck’s Zilovertamab Vedotin Shows 100% CR Rate in Phase II Study for DLBCL: ASH Presentation
US pharmaceutical giant Merck (NYSE: MRK) has revealed promising data from the Phase II waveLINE-007...
Merck Initiates Phase III MOVE-NOW Study for Lagevrio COVID-19 Antiviral
US pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced the commencement of the...
Sacituzumab Tirumotecan Earns FDA Breakthrough Therapy Designation for EGFR Mutated NSCLC
Sacituzumab tirumotecan (SKB264/MK-2870), a TROP2-targeted antibody drug conjugate (ADC) co-developed by Merck, Sharp & Dohme...
Merck’s Recarbrio Approved by NMPA for Hospital-Acquired Infections and Complicated UTIs
US pharmaceutical major Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK) has announced that it...
Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH
US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced positive interim analysis results...
Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH
US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced favorable interim analysis results...
Merck KGaA Partners with NTU Singapore to Drive Digital Transformation with Trust Technology
Merck KGaA (NYSE: MRK) has entered into a Memorandum of Understanding with the Digital Trust...
MSD Partners with Cancer Foundation of China for HPV Vaccine Donation Program
Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a donation agreement with the...
MSD China to Streamline Diabetes Business Amid Volume-Based Procurement Inclusion
The China unit of US pharmaceutical giant Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK)...
China Grants Marketing Approval for MSD’s Welireg for von Hippel-Lindau Disease Tumors
China’s National Medical Products Administration has issued marketing approval for Merck, Sharp & Dohme’s (MSD;...
MSD Announces Positive Topline Results from Phase III Subcutaneous Keytruda Trial
US-based Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has released positive topline results from...
LaNova Medicines Inks Licensing Deal with Sino Biopharmaceutical for Cancer Therapies in China
Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced another licensing deal, signing...
EMA’s CHMP Recommends Approval for MSD’s Keytruda Combo in Mesothelioma Treatment
Merck, Sharp & Dohme Inc., (MSD; NYSE: MRK), a leading US pharmaceutical company, has announced...